| [1] |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48. DOI: 10.3322/caac.21763.
|
| [2] |
Litvin IE, Paganella MP, Wendland EM, et al. Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis[J]. Syst Rev, 2020, 9(1): 66. DOI: 10.1186/s13643-020-01306-9.
pmid: 32216835
|
| [3] |
Lo Gullo R, Wen H, Reiner JS, et al. Assessing PD-L1 expression status using radiomic features from contrast-enhanced breast MRI in breast cancer patients: initial results[J]. Cancers (Basel), 2021, 13(24): 6273. DOI: 10.3390/cancers13246273.
|
| [4] |
檀双秀, 张一丹, 王颖, 等. 常规超声联合剪切波弹性成像鉴别非肿块型导管原位癌和浸润性乳腺癌的价值[J]. 国际肿瘤学杂志, 2024, 51(12): 743-748. DOI: 10.3760/cma.j.cn371439-20240727-00126.
|
| [5] |
檀双秀, 覃心妍, 孔文韬, 等. 瘤内及瘤周超声影像组学联合常规超声参数预测三阴性乳腺癌新辅助治疗病理完全缓解的价值[J]. 中华超声影像学杂志, 2025, 34(4): 295-302. DOI: 10.3760/cma.j.cn131148-20250122-00037.
|
| [6] |
Han X, Guo Y, Ye H, et al. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response[J]. Breast Cancer Res, 2024, 26(1): 18. DOI: 10.1186/s13058-024-01776-y.
pmid: 38287356
|
| [7] |
McDonald ES, Clark AS, Tchou J, et al. Clinical diagnosis and management of breast cancer[J]. J Nucl Med, 2016, 57 Suppl 1: 9S-16S. DOI: 10.2967/jnumed.115.157834.
|
| [8] |
Sigurjonsdottir G, De Marchi T, Ehinger A, et al. Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohisto-chemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort[J]. Breast Cancer Res Treat, 2025, 210(2): 271-284. DOI: 10.1007/s10549-024-07561-x.
|
| [9] |
Jin M, Fang J, Peng J, et al. PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies[J]. Mol Cancer, 2024, 23(1): 266. DOI: 10.1186/s12943-024-02176-8.
pmid: 39614285
|
| [10] |
Huang W, Ran R, Shao B, et al. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis[J]. Breast Cancer Res Treat, 2019, 178(1): 17-33. DOI: 10.1007/s10549-019-05371-0.
|
| [11] |
Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer[J]. N Engl J Med, 2022, 387(3): 217-226. DOI: 10.1056/NEJMoa2202809.
|
| [12] |
Bear HD, Deng X, Bandyopadhyay D, et al. T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy[J]. J Immunother Cancer, 2025, 13(2): e010294. DOI: 10.1136/jitc-2024-010294.
|
| [13] |
国家病理质控中心, 中华医学会病理学分会, 中国临床肿瘤学会肿瘤病理专家委员会. 实体肿瘤PD-L1免疫组织化学检测专家共识(2021版)[J]. 中华病理学杂志, 2021, 50(7): 710-718. DOI: 10.3760/cma.j.cn112151-20210228-00172.
|
| [14] |
胡雪歌, 彭媛, 刘雨璐, 等. 基于多模态MRI影像组学预测模型预测乳腺癌PD-L1表达水平的研究[J]. 中华普通外科杂志, 2024, 39(8): 620-625. DOI: 10.3760/cma.j.cn113855-20240326-00223.
|
| [15] |
Choudhery S, Gomez-Cardona D, Favazza CP, et al. MRI radiomics for assessment of molecular subtype, pathological complete response, and residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy[J]. Acad Radiol, 2022, 29(Suppl 1): S145-S154. DOI: 10.1016/j.acra.2020.10.020.
|
| [16] |
Zheng YM, Yuan MG, Zhou RQ, et al. A computed tomography-based radiomics signature for predicting expression of programmed death ligand 1 in head and neck squamous cell carcinoma[J]. Eur Radiol, 2022, 32(8): 5362-5370. DOI: 10.1007/s00330-022-08651-4.
|
| [17] |
Bracci S, Dolciami M, Trobiani C, et al. Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients[J]. Radiol Med, 2021, 126(11): 1425-1433. DOI: 10.1007/s11547-021-01399-9.
pmid: 34373989
|
| [18] |
Xu H, Liu J, Chen Z, et al. Intratumoral and peritumoral radiomics based on dynamic contrast-enhanced MRI for preoperative prediction of intraductal component in invasive breast cancer[J]. Eur Radiol, 2022, 32(7): 4845-4856. DOI: 10.1007/s00330-022-08539-3.
|
| [19] |
Wu Z, Lin Q, Wang H, et al. Intratumoral and peritumoral radiomics based on preoperative MRI for evaluation of programmed cell death ligand-1 expression in breast cancer[J]. J Magn Reson Imaging, 2024, 60(2): 588-599. DOI: 10.1002/jmri.29109.
|
| [20] |
Gülmez B. Deep learning based colorectal cancer detection in medical images: a comprehensive analysis of datasets, methods, and future directions[J]. Clin Imaging, 2025, 125: 110542. DOI: 10.1016/j.clinimag.2025.110542.
|
| [21] |
Wu J, Li Y, Gong W, et al. Multi-modality radiomics diagnosis of breast cancer based on MRI, ultrasound and mammography[J]. BMC Med Imaging, 2025, 25(1): 265. DOI: 10.1186/s12880-025-01767-1.
pmid: 40615781
|